Jian Feng
Henan University of Science and Technology(CN)National University of Defense Technology(CN)Nantong University(CN)Shanghai Chest Hospital(CN)Soochow University(CN)Affiliated Hospital of Nantong University(CN)Ministry of Agriculture(BW)Wuhan Prevention and Treatment Center for Occupational Diseases(CN)Second People's Hospital of NanTong(CN)Yancheng Third People's Hospital(CN)Economic Research Institute(BG)Ministry of Agriculture(CZ)First Affiliated Hospital of Soochow University(CN)Ministry of Agriculture(TN)Henan Provincial Center for Disease Control and Prevention(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Pancreatic and Hepatic Oncology Research, Cancer Immunotherapy and Biomarkers, Peptidase Inhibition and Analysis, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study(2022)218 cited
- → Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)(2022)164 cited
- → Surgical techniques for early-stage thymoma: Video-assisted thoracoscopic thymectomy versus transsternal thymectomy(2013)117 cited
- → Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)(2016)112 cited
- → Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation(2020)105 cited
- →